Company developing new way to increase GDNF in the brain which may reverse PD

This company is developing some new technology to increase GDNF production in the brain. GDNF has shown success in reversing symptoms of people with PD and a return to 'normal' life. I personally think this is the way to go and it gives me hope and I think it will for you too. This technology combined with fast walking may give us what we are looking for.

Last edited by

7 Replies

  • This DOES sound promising, although sometimes these possible cures seem to drop off the radar. I sure hope this one is going to succeed!!

    Thanks for posting the link.

  • I really hope so too. For all of us!

  • I don't want to rain on anyone's parade, but after listening to this recent podcast,

    the conclusion seems to be that Growth Factors is a story again of "high hopes and dashed expectations." The goal of "stopping the disease," is still eluding our grasp. Although the message on GDNF is disappointing, the tape tells a fascinating story.

    Delivery of the GDNF is not the only problem. Two other, more basic obstacles, are in the way, rendering the GDNF ineffective: a) by 5 years after diagnosis, too few dopamine neurons to be reinvigorated are left alive, and b) alpha synuclein "gums up the dopamine receptors."

    But it's not a dead-end. The expert interviewed, Dr. Jeffrey Kordower, mentions some new research targets that now look promising, and which focus on other symptoms that go beyond dopamine, in particular, balance and dementia.

  • I agree with you that neurogenisis seems the way forward but we can encourage this ourselves. We don't need some company to make a mint by producing an artificial stimulant. Read Dr Brant Cortright "Neurogenisis diet and lifestyle".

  • Thank you for sharing this info

  • "Medicxi will invest up to €9m ($10m) in the asset-centric company *to show clinical efficacy* " - meaning they have not started human studies. This has to go through phase 1, 2, & 3 testing to get approved and they have not even started. Further down in the article we see: " "An mGluR4 PAM is ready to enter Phase II at Prexton Therapeutics " - well, that's not quite right, they are still in phase 1, so they are a little bit ahead:

  • park_bear, thank you for being so on top of it! I really appreciate your responses.

You may also like...